Cargando…

Effectiveness of Disinfecting Caps for Intravenous Access Points in Reducing Central Line-Associated Bloodstream Infections, Clinical Utilization, and Cost of Care During COVID-19

PURPOSE: Intravenous (IV) access point protectors, serving as passive disinfection devices and a cover between line accesses, are available to help reduce the risk of central line-associated bloodstream infections (CLABSIs). This low-maintenance disinfection solution is particularly valuable in situ...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Yuefeng, Griffin, Leah P, Ertmer, Kari, Bernatchez, Stéphanie F, Kärpänen, Tarja J, Palka-Santini, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290837/
https://www.ncbi.nlm.nih.gov/pubmed/37366386
http://dx.doi.org/10.2147/CEOR.S404823
_version_ 1785062574577942528
author Hou, Yuefeng
Griffin, Leah P
Ertmer, Kari
Bernatchez, Stéphanie F
Kärpänen, Tarja J
Palka-Santini, Maria
author_facet Hou, Yuefeng
Griffin, Leah P
Ertmer, Kari
Bernatchez, Stéphanie F
Kärpänen, Tarja J
Palka-Santini, Maria
author_sort Hou, Yuefeng
collection PubMed
description PURPOSE: Intravenous (IV) access point protectors, serving as passive disinfection devices and a cover between line accesses, are available to help reduce the risk of central line-associated bloodstream infections (CLABSIs). This low-maintenance disinfection solution is particularly valuable in situations with excessive workloads. This study examined the effect of a disinfecting cap for an IV access point on CLABSI rates, hospital length of stay, and cost of care in an inpatient setting during the coronavirus disease 2019 (COVID-19) pandemic. METHODS: The study utilized data from the Premier Healthcare Database, focusing on 200,411 hospitalizations involving central venous catheters between January 2020 and September 2020. Among these cases, 7423 patients received a disinfecting cap, while 192,988 patients did not use any disinfecting caps and followed the standard practice of hub scrubbing. The two cohorts, Disinfecting Cap and No-Disinfecting Cap groups, were compared in terms of CLABSI rates, hospital length of stay (LOS), and hospitalization costs. The analysis accounted for baseline group differences and random clustering effects by employing a 34-variable propensity score and mixed-effect multiple regression, respectively. RESULTS: The findings demonstrated a significant 73% decrease in CLABSI rates (p= 0.0013) in the Disinfecting Cap group, with an adjusted CLABSI rate of 0.3% compared to 1.1% in the No-Disinfecting Cap group. Additionally, the Disinfecting Cap group exhibited a 0.5-day reduction in hospital stay (9.2 days versus 9.7 days; p = 0.0169) and cost savings of $6703 ($35,604 versus $42,307; p = 0.0063) per hospital stay compared to the No-Disinfecting Cap group. CONCLUSION: This study provides real-world evidence that implementing a disinfecting cap to protect IV access points effectively reduces the risk of CLABSIs in hospitalized patients compared to standard care, ultimately optimizing the utilization of healthcare resources, particularly in situations where the healthcare system is under significant strain or overloaded.
format Online
Article
Text
id pubmed-10290837
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-102908372023-06-26 Effectiveness of Disinfecting Caps for Intravenous Access Points in Reducing Central Line-Associated Bloodstream Infections, Clinical Utilization, and Cost of Care During COVID-19 Hou, Yuefeng Griffin, Leah P Ertmer, Kari Bernatchez, Stéphanie F Kärpänen, Tarja J Palka-Santini, Maria Clinicoecon Outcomes Res Original Research PURPOSE: Intravenous (IV) access point protectors, serving as passive disinfection devices and a cover between line accesses, are available to help reduce the risk of central line-associated bloodstream infections (CLABSIs). This low-maintenance disinfection solution is particularly valuable in situations with excessive workloads. This study examined the effect of a disinfecting cap for an IV access point on CLABSI rates, hospital length of stay, and cost of care in an inpatient setting during the coronavirus disease 2019 (COVID-19) pandemic. METHODS: The study utilized data from the Premier Healthcare Database, focusing on 200,411 hospitalizations involving central venous catheters between January 2020 and September 2020. Among these cases, 7423 patients received a disinfecting cap, while 192,988 patients did not use any disinfecting caps and followed the standard practice of hub scrubbing. The two cohorts, Disinfecting Cap and No-Disinfecting Cap groups, were compared in terms of CLABSI rates, hospital length of stay (LOS), and hospitalization costs. The analysis accounted for baseline group differences and random clustering effects by employing a 34-variable propensity score and mixed-effect multiple regression, respectively. RESULTS: The findings demonstrated a significant 73% decrease in CLABSI rates (p= 0.0013) in the Disinfecting Cap group, with an adjusted CLABSI rate of 0.3% compared to 1.1% in the No-Disinfecting Cap group. Additionally, the Disinfecting Cap group exhibited a 0.5-day reduction in hospital stay (9.2 days versus 9.7 days; p = 0.0169) and cost savings of $6703 ($35,604 versus $42,307; p = 0.0063) per hospital stay compared to the No-Disinfecting Cap group. CONCLUSION: This study provides real-world evidence that implementing a disinfecting cap to protect IV access points effectively reduces the risk of CLABSIs in hospitalized patients compared to standard care, ultimately optimizing the utilization of healthcare resources, particularly in situations where the healthcare system is under significant strain or overloaded. Dove 2023-06-21 /pmc/articles/PMC10290837/ /pubmed/37366386 http://dx.doi.org/10.2147/CEOR.S404823 Text en © 2023 Hou et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Hou, Yuefeng
Griffin, Leah P
Ertmer, Kari
Bernatchez, Stéphanie F
Kärpänen, Tarja J
Palka-Santini, Maria
Effectiveness of Disinfecting Caps for Intravenous Access Points in Reducing Central Line-Associated Bloodstream Infections, Clinical Utilization, and Cost of Care During COVID-19
title Effectiveness of Disinfecting Caps for Intravenous Access Points in Reducing Central Line-Associated Bloodstream Infections, Clinical Utilization, and Cost of Care During COVID-19
title_full Effectiveness of Disinfecting Caps for Intravenous Access Points in Reducing Central Line-Associated Bloodstream Infections, Clinical Utilization, and Cost of Care During COVID-19
title_fullStr Effectiveness of Disinfecting Caps for Intravenous Access Points in Reducing Central Line-Associated Bloodstream Infections, Clinical Utilization, and Cost of Care During COVID-19
title_full_unstemmed Effectiveness of Disinfecting Caps for Intravenous Access Points in Reducing Central Line-Associated Bloodstream Infections, Clinical Utilization, and Cost of Care During COVID-19
title_short Effectiveness of Disinfecting Caps for Intravenous Access Points in Reducing Central Line-Associated Bloodstream Infections, Clinical Utilization, and Cost of Care During COVID-19
title_sort effectiveness of disinfecting caps for intravenous access points in reducing central line-associated bloodstream infections, clinical utilization, and cost of care during covid-19
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290837/
https://www.ncbi.nlm.nih.gov/pubmed/37366386
http://dx.doi.org/10.2147/CEOR.S404823
work_keys_str_mv AT houyuefeng effectivenessofdisinfectingcapsforintravenousaccesspointsinreducingcentrallineassociatedbloodstreaminfectionsclinicalutilizationandcostofcareduringcovid19
AT griffinleahp effectivenessofdisinfectingcapsforintravenousaccesspointsinreducingcentrallineassociatedbloodstreaminfectionsclinicalutilizationandcostofcareduringcovid19
AT ertmerkari effectivenessofdisinfectingcapsforintravenousaccesspointsinreducingcentrallineassociatedbloodstreaminfectionsclinicalutilizationandcostofcareduringcovid19
AT bernatchezstephanief effectivenessofdisinfectingcapsforintravenousaccesspointsinreducingcentrallineassociatedbloodstreaminfectionsclinicalutilizationandcostofcareduringcovid19
AT karpanentarjaj effectivenessofdisinfectingcapsforintravenousaccesspointsinreducingcentrallineassociatedbloodstreaminfectionsclinicalutilizationandcostofcareduringcovid19
AT palkasantinimaria effectivenessofdisinfectingcapsforintravenousaccesspointsinreducingcentrallineassociatedbloodstreaminfectionsclinicalutilizationandcostofcareduringcovid19